

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
16 March 2023 (16.03.2023)



(10) International Publication Number  
**WO 2023/035068 A1**

(51) International Patent Classification:

A61K 39/00 (2006.01) C07C 69/28 (2006.01)  
A61K 9/51 (2006.01) C07C 69/527 (2006.01)  
A61K 9/127 (2006.01) C07C 69/533 (2006.01)  
A61K 39/385 (2006.01) C07C 69/587 (2006.01)  
A61K 47/54 (2017.01) C07C 69/732 (2006.01)  
A61P 37/02 (2006.01) C07J 7/00 (2006.01)  
C07C 59/44 (2006.01) C12N 15/10 (2006.01)

(21) International Application Number:

PCT/CA2022/051340

(22) International Filing Date:

07 September 2022 (07.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/241,625 08 September 2021 (08.09.2021) US

(71) Applicant: **INTEGRATED NANOTHERAPEUTICS INC.** [CA/CA]; Suite 205, 4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA).

(72) Inventors: **CHEN, Sam**; c/o Integrated Nanotherapeutics Inc., Suite 205-4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA). **NGUYEN, Anne**; c/o Integrated Nanotherapeutics Inc., Suite 205-4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA). **ZAIFMAN, Joshua**; c/o Integrated Nanotherapeutics Inc., Suite 205-4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA).

(74) Agent: **WILKE, Mark** et al.; Gowling WLG (Canada) LLP, 2300-550 Burrard Street, Vancouver, British Columbia V6C 2B5 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE




FIG. 1A

(57) Abstract: An immunomodulatory combination including: (i) a lipid conjugate comprising an immunomodulatory agent covalently linked to a lipophilic moiety by a cleavable linkage or through a cleavable linker; and (ii) an antigen and/or one or more nucleic acids that encode the antigen. The antigen is a protein, polypeptide, peptide, lipoprotein, glycolipid, polynucleotide, or polysaccharide. The lipid conjugate and the antigen and/or the one or more nucleic acids that encode the antigen are formulated in separate delivery vehicles or co-formulated in the same delivery vehicle.